References

CD40 agonist antibodies in cancer immunotherapy

10.1146/annurev-med-062518-045435 · 2020 · External reference

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

10.3109/08923973.2014.890626 · 2014 · External reference

Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells

10.1007/s00262-014-1561-8 · 2014 · External reference

CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models

10.1093/neuonc/nov090 · 2015 · External reference

APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application

10.1007/s00262-020-02814-2 · 2021 · External reference

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

10.1016/s1470-2045(20)30532-5 · 2021 · External reference

New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)

10.1136/esmoopen-2019-000510 · 2019 · External reference

A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy

10.1158/1078-0432.ccr-23-0475 · 2024 · External reference

Agonistic CD40 antibodies in cancer treatment

10.3390/cancers13061302 · 2021 · External reference

Mapping RNA-seq reads with STAR

10.1002/0471250953.bi1114s51 · 2015 · External reference

RSeQC: quality control of RNA-seq experiments

10.1093/bioinformatics/bts356 · 2012 · External reference

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

10.1093/bioinformatics/btt656 · 2014 · External reference

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

10.1186/s13059-014-0550-8 · 2014 · External reference

clusterProfiler 4.0: a universal enrichment tool for interpreting omics data

10.1016/j.xinn.2021.100141 · 2021 · External reference

The Molecular Signatures Database (MSigDB) hallmark gene set collection

10.1016/j.cels.2015.12.004 · 2015 · External reference

Fast and accurate short read alignment with Burrows-Wheeler transform

10.1093/bioinformatics/btp324 · 2009 · External reference

The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data

10.1101/gr.107524.110 · 2010 · External reference

A framework for variation discovery and genotyping using next-generation DNA sequencing data

10.1038/ng.806 · 2011 · External reference

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

10.1101/gr.129684.111 · 2012 · External reference

Strelka2: fast and accurate calling of germline and somatic variants

10.1038/s41592-018-0051-x · 2018 · External reference

Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications

10.1038/ng.3036 · 2014 · External reference

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

10.1038/nbt.2514 · 2013 · External reference

SomaticSniper: identification of somatic point mutations in whole genome sequencing data

10.1093/bioinformatics/btr665 · 2012 · External reference

Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines

10.1016/j.cels.2018.03.002 · 2018 · External reference

FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

10.1093/nar/gkw520 · 2016 · External reference

The Ensembl Variant Effect Predictor

10.1186/s13059-016-0974-4 · 2016 · External reference

Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells

10.1182/blood-2009-04-217604 · 2009 · External reference

Using synthetic templates to design an unbiased multiplex PCR assay

10.1038/ncomms3680 · 2013 · External reference

Ultra-sensitive detection of rare T cell clones

10.1016/j.jim.2011.09.001 · 2012 · External reference

Sufficient sampling for asymptotic minimum species richness estimators

10.1890/07-2147.1 · 2009 · External reference

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

10.1038/s41591-022-01829-9 · 2022 · External reference

A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1/PD-L1

10.1158/1078-0432.ccr-21-0903 · 2021 · External reference

A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

10.1186/s12943-023-01884-x · 2023 · External reference

A phase 2 study of sotigalimab, a CD40 agonist antibody, plus concurrent chemoradiation as neoadjuvant therapy for esophageal and gastroesophageal junction cancers

10.1158/2767-9764.crc-24-0513 · 2025 · External reference

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

10.4161/cc.21842 · 2012 · External reference

Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer

10.1126/scitranslmed.abd1346 · 2021 · External reference

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies

10.1016/j.ccell.2014.11.001 · 2015 · External reference